This article is more than 5 years old. Information may no longer be current.
Top takeaways from ADA 2019
Endocrine Today has compiled a list of the top five news reports posted from the American Diabetes Association 79th Scientific Sessions, held June 7-11, 2019, in San Francisco.
Healio.com/Endocrinology readers were interested in dulaglutide’s effect on cardiovascular risk, how oral semaglutide compares with other diabetes drugs, CAROLINA results that “vindicate” sulfonylurea glimepiride, and much more.
REWIND: Dulaglutide reduces CV, renal risk in broad type 2 diabetes population
In a large cohort of adults with type 2 diabetes with and without established cardiovascular disease, the once-weekly GLP-1 receptor agonist dulaglutide reduced the risk for nonfatal myocardial infarction, nonfatal stroke and CV death by 12% compared with placebo.
PIONEER: Oral semaglutide proves superior to empagliflozin, noninferior to liraglutide for lowering HbA1c
Favorable results from two PIONEER trials of an oral version of the GLP-1 receptor agonist semaglutide were presented at the American Diabetes Association Scientific Sessions.
PREVIEW: Intensive weight loss, behavior change prevents conversion to type 2 diabetes
An initial weight loss of at least 8% over 8 weeks using meal replacement products followed by a lifestyle intervention of diet and physical activity markedly reduced the number of new cases of type 2 diabetes in a cohort of adults with prediabetes.
CAROLINA: Active-comparator study ‘vindicates’ glimepiride for CV safety
A head-to-head comparison of the sulfonylurea glimepiride against the DPP-IV inhibitor linagliptin in a cohort of more than 6,000 adults with type 2 diabetes demonstrated no between-group differences for incidence of nonfatal myocardial infarction, nonfatal stroke and cardiovascular death during a median of 6 years.
‘Medical bypass’ with triple gut-hormone infusion reduces glucose levels, body weight
Among adults with prediabetes or type 2 diabetes and obesity, subcutaneous infusion of the gut hormones GLP-1, oxyntomodulin and peptide YY led to improved glucose levels and weight loss vs. placebo and less glucose variability vs. Roux-en-Y gastric bypass.